Introduction Cardiovascular disease (CVD) is the leading cause of morbidity and mortality
globally. With advances in early diagnosis and treatment of CVD and increasing life …

Introduction: Pharmacogenomic testing can indicate which drugs may have limited
therapeutic action or lead to adverse effects, hence guiding rational and safe prescribing …

Background and Purpose: Data about variations in stroke incidence and subsequent major
adverse outcomes are essential to inform secondary prevention and prioritizing resources to …

Background Although obesity is a well-recognised risk factor for cardiovascular disease
(CVD), the impact of long-term body mass index (BMI) changes in overweight or obese …

Familial hypercholesterolaemia (FH) is a common inherited disorder, causing lifelong
elevated low-density lipoprotein cholesterol (LDL-C). Most individuals with FH remain …

Background The association between obesity, major adverse cardiovascular events
(MACE), and mortality in patients with incident stroke is not well established. We assessed …

Background Patients with ischemic stroke are considered a very high risk population for
subsequent cardiovascular events and guidelines recommend intensive preventive …

Objectives Guidance recommends statin treatment in familial hypercholesterolaemia (FH) to
achieve at least a 50% reduction in low-density lipoprotein cholesterol (LDL-C). We …

Background and aims Familial hypercholesterolaemia (FH) is a known major cause of
premature heart disease. However, the risks of atherosclerotic disease in other vascular …

Individuals developing stroke have varying clinical characteristics, demographic, and
biochemical profiles. This heterogeneity in phenotypic characteristics can impact on …